Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.98 ▼ -0.06
(-2.94%)
MKT CAP: $193.0M • VOL: 255.5K
52W L $1 52W H $3
ROARABLE / RQD
B+ • 78/100
PIOTROSKI
7 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$2
MEDIAN
$2
MEAN
$2
HIGH
$3
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CGEN TAPE
CGEN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $2.40 | $2.28 | 2025-02-14 | $1.80 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $2.49 | $2.34 | 2025-02-06 | $1.86 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $2.26 | $2.18 | 2025-01-29 | $1.90 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $2.02 | — | 2025-01-17 | $1.94 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $1.74 | $1.88 | 2025-01-09 | $1.76 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $2.36 | $2.06 | 2024-12-18 | $1.72 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $1.92 | $2.00 | 2024-12-04 | $1.84 | -4.3% | 48% | C |